Moderna Stock Has Doubled This Year Amid Upcoming FDA Decision on Influenza Vaccine
Moderna (NASDAQ: MRNA) shares have more than doubled this year as investors anticipate a potential approval of its influenza vaccine, mRNA-1010. The U.S. Food and Drug Administration is expected to decide by August 5 whether to approve the vaccine following an advisory committee's unanimous recommendation in favor.
Tickers: $MRNA
Topics: biotech flu vaccine mRNA technology vaccines